Glossary, xi, 
Chapter 1 What on Earth is Nitric Oxide Doing Here?, 1, 
Chapter 2 Stopping Clots, 12, 
Chapter 3 How We Make NO, 19, 
Chapter 4 Transporting NO, 26, 
Chapter 5 Drugs That Release NO, 32, 
Chapter 6 Discovering and Making NO, 40, 
Chapter 7 Making Smog – NO Becomes a Villain, 49, 
Chapter 8 NO – a Not So Simple Little Molecule, 57, 
Chapter 9 NO and Transition Metals, 67, 
Chapter 10 Removing the Villain – Catalytic Converters, 74, 
Chapter 11 NO in Our Defences, 86, 
Chapter 12 NO and Tumour Growth, 97, 
Chapter 13 Bone, Joints and NO, 103, 
Chapter 14 NO is Skin Deep, 110, 
Chapter 15 NO in Nerves, 115, 
Chapter 16 The Truth About Viagra, 126, 
Chapter 17 NO From NOS – Detractors and Stimulants, 129, 
Chapter 18 Why Does Soil Evolve NO?, 135, 
Chapter 19 NO is Everywhere, 144, 
Chapter 20 Reflections, 150, 
Subject Index, 152,

CHAPTER 1

What on Earth is Nitric Oxide Doing Here?

The year 1952 was a bad one for Londoners. The city was frequently shrouded in smog – something between a smoke and a fog – causing traffic chaos and considerable physical distress, particularly amongst the more elderly members of the population. Smog forms when the moisture in a fog, for which London had long been famous, condenses around tiny particles from industrial emissions. Then sulphur dioxide, coming from the burning of coal rich in sulphur in open fires, dissolves in the moisture to give the acrid taste so characteristic of smog. The authorities took rapid action to reduce the amount of smoke and sulphur dioxide released into the air in urban areas. London's smog episodes were quickly eradicated.

London was by no means the only city with smog problems. For some years similar measures had been taken in Los Angeles to reduce smoke and particulate emissions, but the chronic smog problem had failed to ease. It transpired, much to the surprise of the local residents, that the Los Angeles smog had a different cause. Car exhaust fumes, in which the air above Los Angeles abounded, contained not only carbon dioxide and water but also traces of two oxides of nitrogen (nitric oxide, NO, and nitrogen dioxide, NO2) as well as volatile organic compounds. To complicate matters further, the strong Californian sunlight provided suitable energy for a complex series of reactions involving NO which gave a 'photochemical smog'. This was just as distressing as London's industrial smog. Exposure caused eye and bronchial irritation in humans, it blanched the leaves of trees and it accelerated the corrosion of rubber. This is the context in which, before 1987, NO was usually mentioned.

NO is a simple gas and each molecule contains one atom of nitrogen and one atom of oxygen. It just gets mentioned in a school chemistry syllabus. Its most well-known property is that when it is released into the atmosphere it reacts with oxygen to form a brown gas, nitrogen dioxide NO2. This means that if NO forms in the atmosphere the result is a mixture of NO and NO2. Formation of NO does occur naturally, but only in the extreme conditions of a lightning strike. For convenience the mixture of NO and NO2 is known as NOx, pronounced to rhyme with 'socks'. Areas with high NOx concentrations (and hence photochemical smog) sometimes appear on weather charts to warn people to keep away if they can.

Without NOx photochemical smog does not form and so cars in Los Angeles, and elsewhere, are now fitted with catalytic converters to destroy the NOx before it enters the atmosphere. This process is described in more detail later (Chapter 7). With increasing understanding of air pollution NO and NO2 were seen as major villains in the saga and great efforts were made to banish them. However, in 1987 scientists were astonished to learn of another side of NO's complex character: human life depends upon it.

Vessels that carry blood around the body can enlarge, or dilate, and this fixes the amount of blood that is delivered to specific tissues or organs. To see how this happens we have to look at the structure of a blood vessel. The hole in the middle, down which the blood flows, is called the lumen. On the inside of the lumen is a single layer of cells known as the endothelium (endothelial cells) and the wall of the vessel consists largely of smooth muscle (Figure 1.1). It is called smooth because of its appearance under the microscope. When the muscles of the artery wall relax the lumen enlarges and more blood flows through the vessel, provided the heart is pumping properly. If the muscles contract the lumen decreases in size. Then, either less blood flows along the vessel or the heart has to work harder to maintain the flow of the same amount of blood. This is why 'hardening' of the arteries, which prevents muscle relaxation, puts strain on the heart.

It had been known for many years that certain substances, such as acetylcholine, bring about vascular muscle relaxation and some of these substances are released into the bloodstream when relaxation is required. During the late 1970s this matter was under investigation by one of the world's leading muscle physiologists, Robert Furchgott (Figure 1.2), working at the Downstate Medical Center in New York City. He wanted to know how and why substances like acetylcholine affected muscles in this way and he was working with small segments of artery taken from a rabbit. He and his student (John Zawadzki) encountered the most trying of situations in scientific research; their results were not reproducible. In one set of experiments acetylcholine was an active muscle relaxant but in another set of apparently identical experiments it had hardly any relaxing effect at all. The most natural thing to do when this happens is to give up and go fishing, but Furchgott and Zawadzki were made of sterner stuff and they eventually concluded that the result they obtained depended on whether or not the endothelium was intact. It is extremely easy to damage the endothelium when the experiment is being set up.

If the endothelium was undamaged acetylcholine worked fine; remove the endothelium by rubbing, either intentional or accidental, and acetylcholine had no effect at all. Furchgott concluded, quite rightly it is now clear, that acetylcholine was not acting directly on the muscle cells but on the endothelial cells which, in turn, produced another chemical species that diffused into the surrounding muscle and began the process of relaxation. Such a substance is called a messenger molecule as it tells the muscles what to do. Furchgott named this particular messenger molecule the 'endothelium-derived relaxing factor'. It was seen as important enough to warrant a set of initials (but not an acronym): EDRF. The chemical identity of the EDRF was a matter of intense study by many scientists during the 1980s. It was assumed to be a complex organic molecule, like most messenger molecules in the body, but it stubbornly resisted identification. You can see the magnitude of the challenge. The EDRF is produced, along with hundreds of other chemicals, by endothelial cells in quantities around a thousand millionth of a gram, well below the limits of detection by normal chemical means.

The problem was solved by an inspired guess and, although the first person to make the suggestion in print was Furchgott himself, the same idea occurred to others. As is described in more detail in Chapter 5, for many years drugs have been available for bringing about relaxation of the muscle in blood vessels. One, glyceryl trinitrate (1.1), is used either as a lozenge or in a puffer by people suffering from angina. Another one, sodium nitroprusside (1.2), is used in the management of cardiac crises to relax vascular muscle and so lessen the workload on the heart. The action of both drugs was discovered by accident and both now have valued places in medical practice. Why they act as muscle relaxants was, in the 1980s, not known but it was generally assumed that, along with many clinical drugs, their mode of action was completely different from that of naturally occurring vascular muscle relaxants, but perhaps this was not correct. Possibly both glyceryl trinitrate and sodium nitroprusside are transformed within the body into something that is also the naturally occurring messenger molecule for effecting vascular muscle relaxation, the mysterious EDRF. Both drugs contain a group of atoms that includes nitrogen and oxygen and so, the speculation went, the EDRF could be NO. With hindsight the idea is fairly obvious but at the time it was considered absurd. No-one had ever detected NO, or anything like it, in a living system. However, once the suggestion had been made several groups of researchers set about testing it. Two groups were successful in showing that the EDRF is indeed NO. One was led by Louis Ignarro (Figure 1.3), working at the University of California Medical School in Los Angeles and the other was led by Salvador Moncada (Figure 1.4), then at the Wellcome Research Laboratories in Beckenham, England.

They both used a bioassay to establish the identity of the EDRF. What this amounts to is a series of experiments in which a solution of NO and a solution of the EDRF were shown to have identical characteristics with respect to the relaxation of vascular muscle. Thus the evidence, initially, was circumstantial but quite quickly Moncada and his group produced direct evidence for the production of NO from cultured endothelial cells. This is described in more detail later (Chapter 3). Accounts of the work were published simultaneously by the two groups in January 1987. One paper appeared in the journal Nature and the other in Proceedings of the National Academy of Sciences of the USA. The publications were greeted with excitement and some incredulity. Excitement because of their importance in understanding muscle physiology, and incredulity because the findings were was so unexpected. The EDRF was not the complex organic molecule we had expected but a small, diatomic, inorganic molecule. The unexpected nature of the discovery led many to express doubt. NO is produced in lightning strikes and in internal combustion engines, not in mammals at body temperature. Anyway, it is a harmful substance, responsible for photochemical smog, not a benign substance keeping our cardiovascular system in a healthy state. Also, many said that NO is too reactive to function in a living system. It reacts with oxygen to produce NO2, which is highly toxic. None of these objections was sustained on further investigation and it is now firmly established that NO is the EDRF and responsible for vascular muscle relaxation. When sufferers take glyceryl trinitrate for relief of the symptoms of angina the drug is converted into NO, which causes the cardiac arteries to enlarge and more blood to flow. The significance of the discovery was recognized by the award of the 1998 Nobel Prize for Physiology or Medicine, the highest award in the world of science, to three scientists involved in advancing our understanding of muscle relaxation, Ferid Murad, Robert Furchgott and Louis Ignarro. The last two were directly involved in the discovery of NO. Astonishingly the award did not include Salvador Moncada, a matter that has been commented upon publicly on a number of occasions. The papers of the Nobel Committee are not made public for 50 years, long after the deaths of most of those who are so puzzled and disappointed by this omission.

Had that been the end of the NO story it would have been a remarkable discovery, adding another piece to the jigsaw puzzle that makes up the chemistry of life. However, it was only the beginning. This small, diatomic, inorganic molecule turns out to have so many functions in living processes that we wonder how we missed it for so long. At the same time, NO is still polluting the atmosphere and more and more cars are being fitted with catalytic converters to rid the air of this dangerous chemical. Unlike almost any other molecule NO has two diametrically opposed characteristics, giving us both life and death.

It is now firmly established that NO is a cellular messenger molecule bringing about vascular smooth muscle relaxation, but exactly how does it do so? Muscle relaxation is a positive process rather than merely the absence of contraction. It is accompanied by the conversion, within the cell, of guanosine-5-triphosphate (GTP) into cyclic guanosine-3,5-monophosphate (cGMP), shown in Scheme 1.1. This conversion initiates a whole cascade of reactions, leading to protein phosphorylation (attachment of phosphate to a hydroxyl group) and muscle relaxation, processes well understood but too complex to be detailed here. It suffices to know that conversion of GTP into cGMP is catalysed by the enzyme-soluble guanylate cyclase (sGC, also known as guanylyl cyclase), an enzyme activated by NO.

The process observed by Furchgott is shown in Figure 1.5. Acetylcholine binds to a receptor on the surface of an endothelial cell and, in a manner described in more detail later, stimulates the cell to produce NO, which then diffuses into the underlying muscle cell and activates sGC to bring about relaxation. Destroy or damage the endothelium and acetylcholine will have no effect.

sGC is found in the liquid part of almost all mammalian cells, with the highest concentration in the cells of the brain and lungs. It is described as soluble GC because it is in solution and there is another form, particulate GC, that is found in membranes. At the time of writing the three-dimensional structure of sGC has not been determined but the enzyme is known to contain a haem component. Haem is the nonprotein part of haemoglobin and consists of an iron atom held in the centre of a porphyrin ring (1.3 in Scheme 1.2). The protein part of sGC is a dimer of two similar but not identical subunits, named α and β. It is the haem component that makes sGC sensitive to NO. If the haem component is removed, as may happen during isolation and purification, the sensitivity of sGC to NO is lost. The haem component is bound to the enzyme via an imidazole ligand (part of histidine at position 105) in the β subunit. Spectral evidence suggests that the iron is present as Fe2+ bound to imidazole, as in nonoxygenated haemoglobin. The latter readily binds both oxygen and NO. In contrast, sGC, because of structural features in the α subunit, has a remarkably low affinity for oxygen yet readily binds NO. If it were not for this distinction, sGC in cells would be oxygenated and useless as a receptor for NO.

When NO binds to the haem iron of sGC, the bond to the histidine at position 105 (which is trans to the incoming NO) is broken (Scheme 1.2). This results in the formation of a pentaco-ordinated nitrosyl haem complex; the reason for this is explained in Chapter 9. At the same time the iron moves out of the plane of the porphyrin ring, which exposes the catalytic site of the enzyme and allows GTP to enter. Catalytic conversion of GTP into cGMP is dependent on the presence of Mg2+ ions as this cation binds to a number of negatively charged groups in the enzyme and gives the required rigidity to the three-dimensional structure. The other metal known to be necessary for sGC activity is Cu+. Animals fed on a copper-deficient diet exhibit marked loss of endothelium-dependent smooth muscle relaxation. The role of Cu+ ions is unclear but, as described in Chapter 4, Cu+ ions strongly catalyse the release of NO from S-nitrosothiols and so nitrosation of thiols on sGC may be a step in the activation of the enzyme. From this brief account of just one enzyme it is apparent how much inorganic chemistry there is in the chemistry of living processes.

sGC is a constitutive enzyme in that it is present nearly everywhere in animal cells all of the time. In conditions such as septic shock (see Chapter 11), where there is overproduction of NO, it is important to know how far elevated levels of sGC are also responsible for the massive arterial dilation that leads to life-threatening loss of blood pressure. Drugs to inactivate sCG, as well inhibitors of the enzyme responsible for the production of NO (see Chapter 3), may be relevant to the treatment of this condition. The same consideration applies to other faults in the cardiovascular system. Raynaud's phenomenon ('cold finger syndrome') is a troublesome condition that is caused by very restricted flow in peripheral blood vessels, particularly in the fingers. In extreme cases the sufferer cannot go out in cold weather without electrically heated gloves. It is, for some reason, much more common amongst young women than men and tends to lessen with age. The simplest explanation of the effect is that it is due to a shortfall in the production of NO and there is insufficient dilation of minor arteries to allow warming blood to reach the fingers. This condition could be cured by applying NO-releasing drugs to the skin (transdermal delivery of NO), and this is quite feasible. However, experimental evidence suggests that there is also a shortage of sGC in the fingers of sufferers, a situation far more difficult to relieve by means of drugs. Much more research on sGC is required if we are to appreciate its role not only in vascular smooth muscle relaxation, but also in the other living processes in which it plays a part. The elucidation of its activation by NO has done much to stimulate interest in sGC and surely it must be one of the next enzymes to yield its secrets.

(Continues...)

Excerpted from Life, Death and Nitric Oxide by Anthony Butler, Rosslyn Nicholson. Copyright © 2003 The Royal Society of Chemistry. Excerpted by permission of The Royal Society of Chemistry.
All rights reserved. No part of this excerpt may be reproduced or reprinted without permission in writing from the publisher.
Excerpts are provided by Dial-A-Book Inc. solely for the personal use of visitors to this web site.

"About the title" may belong to another edition of this title.

PBShop.store US

Wood Dale, IL, U.S.A.

5-star seller

AbeBooks seller since April 7, 2005

Shipping rates within U.S.A.

Item	7 to 14 business days	7 to 14 business days
First item	£ 0.00	£ 0.00

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.

Payment methods

Store description

We first started out as “The Paperback Exchange,” a chain of physical bookstores where we would part exchange your beloved books for new stories to transport you to faraway places. However, as shopping started to evolve to online shops and marketplaces, we bid our stores goodbye to become “PBShop.” This transition has only allowed us to blossom as we now ship thousands of titles to book lovers across the globe. We pride ourselves in being a community of local book lovers which allows our passion and devotion to shine in everything we do. In 2020 we not only celebrated our 20th birthday but our 1st birthday as being completely employee owned after becoming an E.O.T in September 2019. We are proud to be different and embrace standing apart on a book mountain by working from a virtual inventory which allows us to provide thousands of books that may be difficult to get for your bookshelf or your studies. Working with a number of different suppliers allows us to explore other avenues such as puzzles, sheet music and even stationery so we really do have something for everyone. Life is about being versatile in all realms of existence. If this is your first visit or you are a returning customer, we would like to welcome you to the PBShop family, for there is no friend as loyal as a book. We are a company who put our customers at the centre of everything we do as we understand the importance of reading because once you learn to read, you will forever be free. There are a whole lot of things in this world of ours that we are yet to explore, which is why we will forever inspire curious minds.…

Specialty

Hardbacks, Paperbacks

Seller's business information

Pbshop.co.uk Ltd

Unit 22 Horcott Industrial Estate, Horcott Road
Fairford, United Kingdom GL7 4BX

Contact sellerView this seller's itemsView seller's storefront

Terms of sale

Returns Policy
We ask all customers to contact us for authorisation should they wish to return their order. Orders returned without authorisation may not be credited.
If you wish to return, please contact us within 14 days of receiving your order to obtain authorisation.

Returns requested beyond this time will not be authorised.

Our team will provide full instructions on how to return your order and once received our returns department will process your refund.
Please note the cost to return any unwanted order to us is borne by the buyer.

Should your order arrive damaged, not as advertised or faulty, we must be advised of this within 14 days of delivery. Please contact us so we can find the best solution for you.

Our Customer Care Team can be contacted via emailing paperback-us@paperbackshop.co.uk, or by calling our UK Office on +441285 712 917. We are available 9:00am till 5:30pm GMT weekdays and 9:00am till 1:00pm GMT on Saturdays.

Right of withdrawal

If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.

Information regarding the right of withdrawal

Statutory right to withdraw

You have the right to withdraw from this contract within 14 days without giving any reason.

The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.

To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.

To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.

Effects of withdrawal

If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).

We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.

We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.

We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.

We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.

You shall send back the goods or hand them over to PBShop.store US, Springfield Gardens, New York, U.S.A., +44 1285 712917, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.

Exceptions to the right of withdrawal

The right of withdrawal does not apply to:

The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.

Shipping terms

Books are shipped from our US or UK warehouses. Delivery estimates allow for delivery from either location.

Privacy and security

We are committed to protecting the privacy and security of personal data. This policy tells you how we will collect and use your personal data, and what you should expect in respect of the personal information about you that we have collected.

We are PBShop.co.uk Limited (registered in England & Wales with Company No: 9366362). Our registered office is at Swatton Barn, Badbury, Swindon, SN4 0EU, United Kingdom.

The person with responsibility for our data protection compliance is the Managing Director and they can be contacted via email at help@pbshop.store.

We are the data controller of the personal data that we keep and use, and we are therefore responsible for making sure that our systems, processes and people comply with the relevant data protection laws in respect of that personal data.

We will act in respect of personal data to comply with the six principles of the General Data Protection Regulation (“GDPR”), which are:

Lawfulness, fairness and transparency;
Purpose limitation;
Data minimisation;
Accuracy;
Storage limitation;
Integrity and confidentiality.
You have rights in respect of how your personal data can be processed; these include the right to request:

a copy of your personal data;
that inaccurate data is rectified; and
that your personal data is, in certain circumstances, erased or restricted.
You have the right to complain to the Information Commissioner, which you can do by contacting the Information Commissioner’s Office (ICO) directly. Full contact details, including a helpline number, can be found on the ICO website (www.ico.org.uk). This website also has useful information on your rights and our obligations. However, please raise any concerns or issues with us first so that we may deal with this as quickly as possible for you.

COLLECTION, USE AND DISCLOSURE OF PERSONAL DATA
We collect and process data for the following reasons:

personal data collected and created in relation to our selling books and other items; and
personal data relating to our people (which means those people working for our company, or providing services to us, or potentially working or providing services to us, including employees, consultants, temporary or casual workers and contractors).
All of our people are required to abide by our Privacy Policy when handling personal data, and are provided with appropriate data protection training. Any breach of data protection will be taken seriously, and may result in disciplinary action.

Selling books and other items
COLLECTION:
We will collect personal information which may include names, addresses and other information for our customers. This will be done for the management of the commercial relationship with our customers.

We may collect this personal data from you directly, and also from third parties, including publicly available third party sources. Additional personal data will be collected as it is created by or supplied to us in the course of anything we do for you.

USE:
We will use the personal data in the course of making sales and to comply with requirements that we are required to undertake.

We will only use your personal data when the law allows us to. Most commonly, we will use your personal data in the following circumstances:

in performance of a contract (the agreement to sell books and other items); and/or
compliance with a legal obligation; and/or
vital interests of the data subject; and/or
where it is necessary for our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests.
We may also use your personal data in the following situations, which are likely to be far less common:

where we need to protect your interests (or someone else’s interests);
where it is needed in the public interest or for official purposes.
DISCLOSURE:
We may share personal data with third parties as is necessary in the sale of books and other items, including to third party providers who deliver services to support the operation of our company.

In respect of all disclosures of personal data, we will only share the personal information which is necessary for the particular purpose for which it is provided, or where we have another legitimate interest in doing so, and we will ensure that the personal data is appropriately protected.

RETENTION PERIOD:
We will keep personal data only for as long as is necessary to fulfil the purposes for which we collected it, including for the purposes of satisfying any legal, accounting or reporting requirements. Normally, our retention period for personal data collected for this purpose is a minimum of 6 years after the end of the period that we are selling books and other items.

Our people
COLLECTION:
We will collect names, addresses, contact details, education and employment history, identity and other background checks (which may include appropriate criminal and financial checks and confirmation of the right to work in the UK), marital status and information on next of kin and dependents, financial information (such as bank details and NI numbers), date of birth, gender, a copy of your passport and driving licence, performance information and compensation history, recruitment information (including references), salary, benefits, pension and annual leave information, disciplinary and grievance information, photographs, information about your use of our information and communications systems and CCTV footage or other information obtained through electronic means.

We may collect and use special categories of personal data as required in the carrying out of obligations and exercising specific rights of us or the data subject in the field of employment. This may include information relating to matters such as health, racial origin, religious belief and offences or alleged offences.

Personal data may be collected from you during the selection process (for example via your application form and CV) and during your employment (including holiday forms, expense claims, performance reviews, any disciplinary or grievance processes), or from third parties, including referees, health service providers, background check providers.

USE:
Personal data of our people will be used for HR administration and management, both in respect of the selection of people to work for us (including suitability, eligibility and/or fitness to work), and those who do work for us, to include learning and development, disciplinary and security (of people, offices and data) requirements, providing and liaising with benefits providers, business management and planning (including accounting and auditing), paying you and dealing with tax and NI deductions, assessing and deciding on salary reviews and compensation, conducting performance reviews and managing performance, dealing with legal disputes involving you or others, preventing fraud, monitoring your use of our information and communications systems, ensuring compliance with our policies, and equal opportunities monitoring.

We will only use your personal data when the law allows us to. Most commonly, we will use your personal data in the following circumstances:

In performance of a contract with you; and/or
compliance with a legal obligation; and/or
vital interests of the data subject; and/or
where it is necessary for our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests.
We may also use your personal data in the following situations, which are likely to be less common:

where we need to protect your interests (or someone else’s interests);
where it is needed in the public interest or for official purposes.
In respect of all disclosures of personal data, we will only share the personal information which is necessary for the particular purpose for which it is provided, or where we have another legitimate interest in doing so, and we will ensure that the personal data is appropriately protected.

In respect of special categories of personal data, we may process this in the following circumstances:

in limited circumstances with your explicit written consent; and/or
where we need to carry out our legal obligations and in line with our policies; and/or
where it is needed in the public interest (such as for equal opportunities monitoring or in relation to our occupational pension scheme), and in line with our policies; and/or
where it is needed to assess your working capacity on health grounds, subject to appropriate confidentiality safeguards.
Less commonly, we may process this type of information where it is needed in relation to legal claims or where it is needed to protect your (or someone else’s) interests and you are not capable of giving your consent, or where you have already made the information public. We may also process such information about our people (or former people) in the course of our legitimate business activities with the appropriate safeguards.

The special categories of personal data may be used in the following ways:

in relation to leaves of absence, to comply with employment and other laws;
in relation to your physical or mental health, or disability status, to ensure your health and safety in the workplace and to assess your fitness to work, to monitor, manage and administer benefits and absences;
in relation to your race, national or ethnic origin, religious, philosophical or moral beliefs, or your sexual life or sexual orientation, to ensure meaningful equal opportunity monitoring and reporting.
DISCLOSURE:
Personal data may be transferred to service providers who support the operation of our business (such as payroll service providers), to other third parties reasonably necessary in the conduct of our business (including insurers, professional advisors, regulators). These third parties may be acting as processor, or controller of personal data in their own right.

RETENTION PERIOD:
We will keep personal data only for as long as is necessary to fulfil the purposes for which we collected it, including for the purposes of satisfying any legal, accounting or reporting requirements. We will normally keep personal data of applicants who we do not employ for six months after we receive it.

We will keep personal data of employees throughout your employment and normally for a minimum of six years after your employment ends.

Changes to your personal data
It is very important that the personal information that we hold about you is accurate and current. Please tell us if your personal information changes during your relationship with us.

Data Security
We have put in place measures to prevent your personal data from being accidentally lost, used or accessed in an unauthorised way, altered or disclosed. In addition, we limit access to your personal data to those of our people and other third parties who have a business need to know. They will only process your personal data on our instructions and where they have agreed to treat the information confidentially and to keep it secure. We have put in place procedures to deal with any suspected data security breach and will notify you and the ICO of a suspected breach where we are legally required to do so.

Where we store your personal data
We principally store data, both electronically and on file, at our office.

Personal data may be transferred outside of the EEA by processors acting on our behalf. For transfers to countries not considered adequate by the EC, we will ensure that personal data is adequately protected, as required by the GDPR. This would include by use of the Standard Contractual Clauses adopted by the EC to protect personal data.

Your rights
Under certain circumstances, you have the right by law to request:

access to your personal data. This enables you to ask to receive a copy of the personal data that we hold about you and to check that we are lawfully processing it.
correction of the personal data that we hold about you.
erasure of your personal data.
object to processing of your personal data where we are relying on our legitimate interest and there is something about your particular situation which makes you want to object to processing on this ground. You also have the right to object where we are processing your personal information for direct marketing purposes.
restriction of processing of your personal data.
transfer of your personal data to another party.
Links from our website
Our website may, from time to time, contain links to and from the websites of third parties that we permit to make such links. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. We recommend that you check these policies before you submit any personal data to these websites.

CHANGES TO THIS PRIVACY POLICY
Any changes we may make to our privacy policy in the future will be posted on our website, so please ensure that you are viewing the correct version.

Please contact us if you have any questions, comments or requests regarding this Privacy Policy.

Last amended May 2021.

Life, Death and Nitric Oxide

Item description from seller

Bibliographic details

Synopsis

About the title

Excerpt. © Reprinted by permission. All rights reserved.